Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets
NCT01687920
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
25
Enrollment
INDUSTRY
Sponsor class
Conditions
Heart Failure
Interventions
DRUG:
BAY94-8862 (1.25mg)
DRUG:
BAY94-8862 (2.5mg)
DRUG:
BAY94-8862 (5mg)
DRUG:
BAY94-8862 (7.5mg)
DRUG:
BAY94-8862 (10mg)
Sponsor
Bayer